GENESYS Diagnostics^{INC.} **Developmental Delay Microarray**

Information required for testing Patient Information MM/DD/YYYY LAST NAME FIRST NAME* GENDER MI DOB* SEX ADDRESS PHONE NUMBER EMAIL ADDRESS CITY STATE ZIPCODE Billing Information (Please include a copy of insurance card(s) for billing purposes.) *□ CLIENT BILL □ INSURANCE □ SELF PAY □ MEDICARE/MEDICAID (□ PRIMARY □ SECONDARY) RELATIONSHIP: □ SELF □ SPOUSE □ DEPENDENT **INSURANCE NAME** MEMBER/POLICY ID GROUP # POLICY HOLDER NAME POLICY HOLDER DOB TEST INDICATION/ICD-10 CODE(S)* Account Information FACILITY/PRACTICE NAME* PHONE NUMBER FAX NUMBER **ORDERING PHYSICIAN NAME*** Specimen Information PREFERRED SPECIMEN IS BUCCAL SWAB □ PERIPHERAL BLOOD □ BUCCAL SWAB COLLECTION DATE: MM/DD/YYYY COLLECTION TIME: Test(s) Requested* FRAGILE X SYNDROME (FXS) CYSTIC FIBROSIS (CF) SPINAL MUSCULAR ATROPHY (SMA) DUCHENNE MUSCULAR DYSTROPHY (DMD) FISH Studies FISH STUDIES WILL NOT BE RUN UNLESS BOX IS CHECKED AND OPTIONS BELOW HAVE BEEN CHOSEN FISH FOR SEX CHROMOSOME FISH FOR ANEUPLOIDY FISH FOR MICRODELETION SYNDROMES ABNORMALITIES: Soto syndrome (5q35) □ Angelman syndrome (15q11-13) □ (AneuVysion) X/Y/18/13/21 □ Sex Determination (X/SRY) SRY (Yp11.3) Cri du Chat-syndrome (5p15.2) □ X/Y/18 ONLY □ Steroid Sulfatase (STS) (Xp22.3) □ Turner Syndrome (CEPX/CEPY) DiGeorge/VCFS/CATCH22 (22q11.2) □ 13/21 ONLY □ Wolf-Hirschhorn syndrome (4p16.3) □ Klinefelter Syndrome (CEPX/CEPY) □ Kallmann syndrome (Xp22.3)

ICD-10 Code(s)*			
🗆 F70	Mild intellectual disabilities	🗆 R47.89	Other speech disturbances
🗆 F71	Moderate intellectual disabilities	🗆 R62.0	Delayed milestone in childhood
🗆 F72	Severe intellectual disabilities	🗆 R62.5	Other unspecified lack of expected normal physiological development in childhood
🗆 F73	Profound intellectual disabilities	🗆 R62.59	Other lack of expected normal physiological development in childhood
🗆 F81.81	Disorder of written expression	🗖 Q18.9	Congenital malformation of face and neck, unspecified
🗆 F81.89	Other developmental disorders of scholastic skills	🗖 Q79.9	Congenital malformation of musculoskeletal system, unspecified
🗆 F81.9	Developmental disorder of scholastic skills, unspecified	🗖 Q89.7	Multiple anomalies
🗆 F82	Specific developmental disorder of motor function	🗖 Q89.8	Other specified congenital malformations
🗆 F79	Unspecified intellectual disabilities	🗖 Q89.9	Congenital malformation, unspecified
🗆 F84.0	Autism spectrum disorder	🗆 Z84.3	Consanguinity
🗆 F88	Developmental delay	🗆 Z84.89	Family history of disease or disorders
🗆 F89	Unspecified Disorder of Development	🗆 Other	
🗆 K55.30	Necrotizing enterocolitis, unspecified		

□ Miller-Dieker syndrome (17p13.3)

□ Prader-Willi syndrome (15q11-13)

□ Smith-Magenis syndrome (17p 11.2)

Patient Authorization and Consent

I understand that I am responsible for providing accurate information about my insurance to Genesys Diagnostics Inc. I understand that Genesys Diagnostics Inc. will be providing testing service and billing my insurance. However, I understand that charges that are not covered by my insurance, including any applicable co- payments and deductibles are my responsibility and I agree to pay such charges promptly.

Patient/Guardian Signature:*

Trisomy 21 - Down Syndrome

Trisomy 13 - Patau Syndrome

Trisomy 18 - Edwards Syndrome

 \Box I do not consent to having my deidentified DNA sample used for internal research purposes.

Healthcare Provider Authorization

I certify that (i) this test is medically necessary, (ii) the patient (or authorized representative on the patient's behalf) has given informed consent (which includes written informed consent or written authorization when required by law) to have this testing performed, and (iii) the informed consent obtained from the patient meets the requirements of applicable law. I agree to provide Genesys, or its designee, any and all additional information reasonably required for this testing to be performed.

Healthcare Provider Signature:*

Medical Necessity Statement: Tests ordered on Medicare patients must follow CMS rules regarding medical necessity and FDA approval guidelines and must include diagnosis, symptoms and reason for testing as indicated in If testing does not come under Medicare guidelines for payment a 'signed' Advanced Beneficiary Notice must be included www.gdilabs.com

8 Enterprise Lane Oakdale, CT 06370 Phone: (860) 574-9172 Fax: (860) 574-9264

info@gdilabs.com

□ Williams Beuren syndrome (7q11.23)

🗆 XIST (Xq13.2)

Other

Date:*



